News & Updates

Updates, press releases, and news on our work on GB-13.

Targepeutics to Present Latest DMG and GBM Data at Society for NeuroOncology Annual Meeting

Targepeutics is presenting the latest efficacy data related to treatment of GBM and DMG tumors with the novel immunotoxin, GB13. This data is presented as a poster presentation during the…

Read More

Targepeutics Announces Phase I SBIR Grant to Support GB-13 Development

Targepeutics announces a Phase I Small Business Innovation Research (SBIR) grant awarded to Dr Randy Schrecengost as Primary Investigator to support preliminary data demonstrating that GB13 can specifically target IL13Rα2-positive…

Read More